nach oben

Erschienen in:

01.12.2010

BRCA1 and BRCA2 families and the risk of skin cancer

verfasst von: Ophira M. Ginsburg, Charmaine Kim-Sing, William D. Foulkes, Parviz Ghadirian, Henry T. Lynch, Ping Sun, Steven A. Narod, Hereditary Breast Cancer Clinical Study Group

Erschienen in: Familial Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma skin cancer. We followed 2729 women with a BRCA1 or BRCA2 mutation for an average of 5.0 years. These women were asked to report new cases of cancer diagnosed in themselves or in their family. The risks of skin cancer were compared for probands with BRCA1 and BRCA2 mutations. Of 1779 women with a BRCA1 mutation, 29 developed skin cancer in the follow-up period (1.6%). Of the 950 women with a BRCA2 mutation, 28 developed skin cancer (3.0%) (OR = 1.83 for BRCA2 versus BRCA1; 95% CI 1.08–3.10; P = 0.02). The odds ratio for basal cell carcinoma was higher (OR = 3.8; 95% CI 1.5–9.4; P = 0.002). BRCA2 mutation carriers are at increased risk for skin cancer, compared with BRCA1 carriers, in particular for basal cell carcinoma.

Ford D, Easton D, Bishop T, Narod S et al (1994) Risk of cancer in BRCA1 mutation carriers. Lancet 343:692–695CrossRefPubMed

The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef

Thompson D, Easton DF (2002) Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365PubMed

Brose M, Rebbeck T, Calzone K et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a cancer risk evaluation program. J Natl Cancer Inst 94:1365–1372PubMed

Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germ-line mutation carriers. Eur J Cancer 35:1248–1257CrossRefPubMed

Bermejo JL, Hemminki K (2004) Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 15:1834–1841CrossRef

Shih H, Nathanson K, Seal S, Collins N, Stratton M, Rebbeck T, Weber B (2000) BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6:4259–4264PubMed

Easton D, Steele L, Fields P, Ormiston W et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on Chromosome 13q12–13. Am J Hum Genet 61:120–128CrossRefPubMed

Moslehi R, Chu W, Karlan B et al (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259–1272CrossRefPubMed

10.

Risch H, McLaughlin J, Cole D, Rosen B et al (2001) Prevalence of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710CrossRefPubMed

11.

Aretini P, D’ Andrea E, Pasini B, Viel A et al (2003) Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat 81:71–79CrossRefPubMed

12.

Streuwing J, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408CrossRef

13.

Goldgar DE, Easton DF, Cannon-Albright L, Skolnick M (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600–1608CrossRefPubMed

14.

Berman D, Costalas J, Schultz D, Grana G, Daly M, Godwin A (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish and non-Jewish individuals. Cancer Res 56:3409–3414PubMed

15.

Hahn S, Greenhalf B, Ellis I, Sina-Frey M et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221CrossRefPubMed

16.

Murphy K, Brune K, Griffin C, Sollenberger J et al (2002) Evaluation of candidate genes MPP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793PubMed

17.

Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1 and BRCA2 mutations. Cancer Res 60:409–416PubMed

18.

Kirchhoff T, Kauff N, Mitra N et al (2004) BRCA mutations and the risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918–2921CrossRefPubMed

19.

Edwards SM, Kote-Jarai Z, Meitz J et al (2003) Two percent of men with early onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1–12CrossRefPubMed

20.

Vazina A, Baniel J, Shtriker A et al (2000) The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83:463–466CrossRefPubMed

21.

Hubert A, Peretz T, Manor O et al (1999) The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921–924CrossRefPubMed

22.

Thorlacius S, Struewing J, Hartge P et al (1998) Population based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337–1339CrossRefPubMed

23.

Sigurdsson S, Thorlaciaus S, Tomasson J et al (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75:758–761CrossRefPubMed

24.

Iscovich J, Abdulrazik M, Cour C et al (2002) Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer 98:42–44CrossRefPubMed

25.

Scott R, Vajdic C, Armstrong B et al (2002) BRCA2 mutations in a population based series of patients with ocular melanoma. Int J Cancer 102:188–191CrossRefPubMed

26.

Niell B, Rennert G, Bonner J, Almog R, Tomsho L, Gruber S (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15–21CrossRefPubMed

27.

Kirchhoff T, Satagopan J, Kauff N et al (2004) Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96:68–70CrossRefPubMed

28.

Chen-Stoyerman R, Figer A, Fidder H et al (2001) The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 84:475–477CrossRef

29.

Drucker L, Stackievitz R, Shpitz B, Yarkoni S (2000) Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Res 20:559–561PubMed

30.

Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226PubMed

31.

Amos CR (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:74–75CrossRefPubMed

32.

Risch H, Narod S (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:73–74PubMed

33.

Pharoah PP, Antoniou A, Hopper J, Easton D (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:75–76CrossRefPubMed

34.

Whittemore AS, Gong G (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:76–77CrossRefPubMed

35.

Burke W, Austin MA (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:78–79CrossRefPubMed

36.

Easton DF, Hopper JL, Thomas DL, Antoniou A, Pharoah PDP, Whittemore AS (2004) Re: breast cancer risks for BRCA1/2 carriers. Science 306:2187–2188CrossRefPubMed

37.

Wacholder S, Struewing JP, Hartage P, Greene MH, Tucker MA (2004) Re: breast cancer risks for BRCA1/2 carriers. Science 306:2188

38.

King MC, New York Breast Cancer Study Group (2004) Re: breast cancer risks for BRCA1/2 carriers. Science 306:2188–2191

39.

Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98(23):1675–1677CrossRefPubMed

40.

Easton DR, Ford D, Bishop DT (1995) Breast and ovarian incidence in BRCA1-mutartion carriers. Am J Hum Genet 56:256–271

41.

Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H (2003) Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5:R175–R186CrossRefPubMed

42.

Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United States: incidence. J Am Acad Derm 30:774–778CrossRefPubMed

43.

SEER 17 (2000–2006). http://seer.cancer.gov

44.

Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 carriers: minireview. British J Cancer 96:11–15CrossRef

45.

Iscovitch J, Abdulrazik M, Cour C et al (2002) Prevalence of the BRCA2 6174delT mutation in uveal melanoma patients. Int J Cancer 98:42–44CrossRef

46.

Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M (2009) Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 8:29–32CrossRefPubMed

47.

Monerrat C, Chompret A, Kannengiesser C, Avril M-F et al (2007) BRCA1, BRCA2, CDKN2a germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 6:453–461CrossRef

48.

Navaraj A, Mori T, El-Deiry WS (2005) Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol Ther 4:1409–1414PubMed

Titel: BRCA1 and BRCA2 families and the risk of skin cancer
verfasst von: Ophira M. Ginsburg
Charmaine Kim-Sing
William D. Foulkes
Parviz Ghadirian
Henry T. Lynch
Ping Sun
Steven A. Narod
Hereditary Breast Cancer Clinical Study Group
Publikationsdatum: 01.12.2010
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-010-9377-y

Springer Medizin

BRCA1 and BRCA2 families and the risk of skin cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning

PALB2: a novel inactivating mutation in a Italian breast cancer family

Hereditary predisposition rather than environmental factor are likely to explain the familial link between uveal melanoma and other cancers

FAP, gastric cancer, and genetic counseling featuring children and young adults: a family study and review

CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland

Communicating genetic risk information within families: a review

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie